Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Ganga Pharmaceuticals Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
Ganga Pharmaceuticals has a total shareholder equity of ₹70.5M and total debt of ₹13.6M, which brings its debt-to-equity ratio to 19.3%. Its total assets and total liabilities are ₹86.5M and ₹16.0M respectively. Ganga Pharmaceuticals's EBIT is ₹84.2K making its interest coverage ratio -0.1. It has cash and short-term investments of ₹298.3K.
Anahtar bilgiler
19.3%
Borç/özkaynak oranı
₹13.58m
Borç
| Faiz karşılama oranı | -0.1x |
| Nakit | ₹298.30k |
| Eşitlik | ₹70.53m |
| Toplam yükümlülükler | ₹15.95m |
| Toplam varlıklar | ₹86.48m |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 539680's short term assets (₹57.5M) exceed its short term liabilities (₹12.0M).
Uzun Vadeli Yükümlülükler: 539680's short term assets (₹57.5M) exceed its long term liabilities (₹4.0M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 539680's net debt to equity ratio (18.8%) is considered satisfactory.
Borcun Azaltılması: 539680's debt to equity ratio has reduced from 36.3% to 19.3% over the past 5 years.
Borç Kapsamı: 539680's operating cash flow is negative, therefore debt is not well covered.
Faiz Kapsamı: 539680 earns more interest than it pays, so coverage of interest payments is not a concern.